United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 1,265 shares of the company’s stock in a transaction that occurred on Thursday, October 19th. The stock was sold at an average price of $119.38, for a total transaction of $151,015.70. Following the transaction, the chief executive officer now owns 1,405 shares of the company’s stock, valued at $167,728.90. The transaction was disclosed in a filing with the SEC, which is available through this link.

United Therapeutics Corporation (UTHR) traded up 1.64% during midday trading on Friday, hitting $121.01. 402,257 shares of the stock traded hands. The stock’s 50-day moving average price is $121.87 and its 200 day moving average price is $125.73. United Therapeutics Corporation has a 52 week low of $111.11 and a 52 week high of $169.89. The company has a market capitalization of $5.26 billion, a price-to-earnings ratio of 14.03 and a beta of 1.49.

United Therapeutics Corporation (NASDAQ:UTHR) last issued its earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) EPS for the quarter, missing the consensus estimate of $3.61 by ($4.86). United Therapeutics Corporation had a return on equity of 20.96% and a net margin of 24.18%. The firm had revenue of $444.60 million during the quarter, compared to analysts’ expectations of $391.53 million. During the same period in the previous year, the firm earned $4.42 earnings per share. The firm’s quarterly revenue was up 7.8% compared to the same quarter last year. On average, equities research analysts predict that United Therapeutics Corporation will post $10.60 EPS for the current year.

WARNING: This story was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/10/21/united-therapeutics-corporation-uthr-ceo-martine-a-rothblatt-sells-1265-shares-of-stock.html.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. APG Asset Management N.V. increased its stake in shares of United Therapeutics Corporation by 24.5% in the third quarter. APG Asset Management N.V. now owns 652,000 shares of the biotechnology company’s stock worth $76,408,000 after buying an additional 128,404 shares during the period. Robeco Institutional Asset Management B.V. increased its stake in shares of United Therapeutics Corporation by 22.1% in the third quarter. Robeco Institutional Asset Management B.V. now owns 158,368 shares of the biotechnology company’s stock worth $18,559,000 after buying an additional 28,625 shares during the period. Assenagon Asset Management S.A. increased its stake in shares of United Therapeutics Corporation by 182.3% in the third quarter. Assenagon Asset Management S.A. now owns 9,264 shares of the biotechnology company’s stock worth $1,086,000 after buying an additional 5,982 shares during the period. Shell Asset Management Co. increased its stake in shares of United Therapeutics Corporation by 112.8% in the third quarter. Shell Asset Management Co. now owns 33,504 shares of the biotechnology company’s stock worth $4,310,000 after buying an additional 17,756 shares during the period. Finally, Dynamic Technology Lab Private Ltd purchased a new position in shares of United Therapeutics Corporation in the second quarter worth $285,000.

A number of research firms recently issued reports on UTHR. UBS AG reiterated a “sell” rating and set a $106.00 price objective on shares of United Therapeutics Corporation in a research report on Thursday, July 6th. ValuEngine upgraded shares of United Therapeutics Corporation from a “buy” rating to a “strong-buy” rating in a research report on Thursday, July 13th. BidaskClub cut shares of United Therapeutics Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th. Jefferies Group LLC reiterated a “sell” rating and set a $105.00 price objective on shares of United Therapeutics Corporation in a research report on Friday, July 14th. Finally, Zacks Investment Research cut shares of United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. Five investment analysts have rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $132.09.

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Insider Buying and Selling by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Stock Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related stocks with our FREE daily email newsletter.